From July 1, 2017, Harvoni will be made available for people with chronic hepatitis C and advanced disease at an earlier stage.
According to PHARMAC, the announcement will see an additional 45 people get access to Harvoni.
The treatment was funded in New Zealand in 2016, but only for people with end-stage liver disease.
Harvoni is a direct-acting antiviral medication which has a cure rate of 90+ per cent, shorter treatment duration and fewer side-effects than past interferon treatments.
Read more here.
Design by Paradigm | Developed by Snipesoft
© The Hepatitis Foundation of New Zealand 2016